

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/847,061	05/01/2001	Guang Yang	P-092-R	4558
21186	7590 12/12/2003		EXAMINER	
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. BOX 2938			LIU, SAMUEL W	
	DLIS, MN 55402		ART UNIT	PAPER NUMBER
			1653	

DATE MAILED: 12/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/847,061	YANG ET AL.			
		Examiner	Art Unit			
		Samuel W Liu	1653			
Period fo	The MAILING DATE of this communication	n appears on the cover sheet w	ith the correspondence address			
A SHOTHE I - Exter after - If the - If NC - Failu - Any rearne	ORTENED STATUTORY PERIOD FOR R MAILING DATE OF THIS COMMUNICATI nsions of time may be available under the provisions of 37 C SIX (6) MONTHS from the mailing date of this communicati period for reply specified above is less than thirty (30) days of period for reply is specified above, the maximum statutory are to reply within the set or extended period for reply will, by reply received by the Office later than three months after the ad patent term adjustment. See 37 CFR 1.704(b).	ON. ERR 1.136(a). In no event, however, may a on. , a reply within the statutory minimum of thingering will apply and will expire SIX (6) MO statute, cause the application to become A	reply be timely filed ty (30) days will be considered timely. NTHS from the mailing date of this communication BANDONED (35 U.S.C. § 133).	1.		
Status	Responsive to communication(s) filed on	07 October 2002 and 07 Octo	har 2002			
	Responsive to communication(s) filed on		<u>5er 2003</u> .			
<i>,</i> —	,	This action is non-final.	toro muono sution on to the mension in			
,	Since this application is in condition for al closed in accordance with the practice un			i		
Dispositi	on of Claims					
5)□ 6)⊠ 7)⊠	Claim(s) 7,13,14 and 16-28 is/are pending in the application. 4a) Of the above claim(s) 16 and 17 is/are withdrawn from consideration. Claim(s) is/are allowed. Claim(s) 7,13,14 and 18-28 is/are rejected. Claim(s) 20 is/are objected to. Claim(s) are subject to restriction and/or election requirement.					
Applicati	ion Papers					
10)	The specification is objected to by the Example The drawing(s) filed on is/are: a) Applicant may not request that any objection Replacement drawing sheet(s) including the other oath or declaration is objected to by the specific transfer of trans	accepted or b) objected to to the drawing(s) be held in abeya correction is required if the drawin	nce. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d	i).		
Priority (under 35 U.S.C. §§ 119 and 120					
* \$ 13) \(\times \) A s s a 14) \(\times \) A	Acknowledgment is made of a claim for for All b) Some * c) None of: 1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International Beet the attached detailed Office action for Acknowledgment is made of a claim for do ince a specific reference was included in to 7 CFR 1.78. 1) The translation of the foreign language Acknowledgment is made of a claim for doceference was included in the first sentence	ments have been received. Iments have been received in a priority documents have been received in a priority documents have been received in a priority documents have been received (PCT Rule 17.2(a)). In a list of the certified copies not mestic priority under 35 U.S.C. he first sentence of the specification has a provisional application has a mestic priority under 35 U.S.C.	Application No In received in this National Stage It received. It is a provisional application or in an Application Data Shebeen received. It is a provisional application or in an Application Data Shebeen received. It is a provisional application Data Shebeen received. It is a provisional application Data Shebeen received.	eet.		
Attachmen	• •					
2) Notic	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-94 mation Disclosure Statement(s) (PTO-1449) Paper N	18) 5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)			

Art Unit: 1653

DETAILED ACTION

Status of the claims

Claims 7, 13-14 and 16-28 are pending.

Applicants' amendment filed 7 October 2003, which amends claims 7 and 13-14, cancels claims 1-6, 8-12 and 15, and adds claims 18-28, has been entered.

Election/Restrictions

Applicant's election (see the response filed 7 October 2003) of Group I, claims (pending) 7 and 13-14 with traverse is acknowledged. The traversal is on the ground(s) that search can be done without serious burden to Examiner, and Groups I and II are classified in the common classes and subclasses not separable. In this regard, examiner has quoted the following statement:

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend** from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined

Application/Control Number: 09/847,061

Art Unit: 1653

Page 3

claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Of the above mentioned pending claims, claims 16-17 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected inventions.

Thus, the elected claims 7, 13-14 and 18-28 are under examination to the extent that they are drawn to the elected invention.

IDS

The references lists in Information disclosure Statements filed 10 January 2002, 5
February 2002, and 6 May 2002 have been received. The references recited in the PTO 1449
Forms of submitted the IDS documents have been considered by Examiner.

Application/Control Number: 09/847,061 Page 4

Art Unit: 1653

Specification/claim Objections

The disclosure is objected to because of the following informalities:

In page 12, line 11, "formula –CH2" should be changed to "formula –CH₂"; the similar

changed should be made throughout the specification.

In claim 20, after "-NH-" add "group".

Appropriate correction is required.

Claim Rejections - 35 USC § 101

35 U.S.C. §101 states:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title.

Claim 7 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter.

Claim 7, as written, do not distinguish the claimed glycopeptide from naturally existing products. The claims do not particularly point out any differences indicating the hand of man. In the absence of the hand of man, the claimed products are considered non-statutory subject matter. *See Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claims should be amended to indicate the hand of the inventor, *e.g.*, by insertion of "isolated" or "purified" as disclosed on example 1 wherein indicate the disclosed composition is prepared through chemical modification. See MPEP 2105.

Claim Rejections - 35 USC § 112, the second paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter that the applicant regards as his invention.

Application/Control Number: 09/847,061 Page 5

Art Unit: 1653

Claims 7, 13-14 and 18-28 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7 is indefinite in the recitation "x is 1 or 2"; where in the claim "x" refers to? Also, claim 7 is unclear as to "or a pharmaceutical acceptable salt, stereoisomer, or prodrug thereof"; is the claimed glycopeptide is a pharmaceutical acceptable salt, stereoisomer, or prodrug? Note that pharmaceutical acceptable salt is not active composition, prodrug is an inactive precursor of a drug, converted into its active form in the body by normal metabolic processes, and that stereoisomer. What is stereoisomer respective to the claimed glycopeptide? Claim 7 does not make it clear that what compound of stereoisomer is. The dependent claims are also rejected.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel Wei Liu whose telephone number is (703) 306-3483. The examiner can normally be reached from 9:00 a.m. to 5:00 p.m. on weekdays. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low, can be reached on 703 308-2923. The fax phone number for the organization where this application or proceeding is assigned is 703 308-4242 or 703 872-9306 (official) or 703 872-9307 (after final). Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 305-4700.

KAREN COCHRANE CARLSON, PH.D

COCHRANE CARLSON, PH.D

COCHRANE CARLSON, PH.D

COCHRANE CARLSON, PH.D

Page 6

Samuel W. Liu, Ph.D.

SWL

November 21, 2003